Ecnoglutide: Research & Studies
Scientific evidence, clinical trials, and research findings
๐TL;DR
- โข3 clinical studies cited
- โขOverall evidence level: moderate
- โข6 research gaps identified
Research Studies
Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog
Ren T, Chen X, Xu Y, et al. (2023) โข Molecular Metabolism
This publication describes the discovery, preclinical characterization, and Phase 1 clinical trial results of ecnoglutide. The molecule was engineered with Ala8Val substitution and C18 fatty diacid for cAMP-biased signaling. In vitro, ecnoglutide showed potent cAMP induction (EC50 = 0.018 nM) but minimal receptor internalization (EC50 > 10,000 nM).
Key Findings
- cAMP induction EC50 = 0.018 nM; receptor internalization EC50 > 10,000 nM
- Superior weight loss compared to semaglutide in rodent models at equivalent doses
- Phase 1 half-life at steady state: 124-138 hours, supporting once-weekly dosing
- Composed entirely of natural amino acids, simplifying manufacturing
Limitations: Phase 1 data limited to 6 weeks of dosing with small sample size; preclinical superiority over semaglutide may not translate to humans
Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial
Ji L, Jiang D, Jiang H, et al. (2024) โข Nature Communications
Phase 2 trial of ecnoglutide in 145 adults with type 2 diabetes. Participants were randomized to 0.4, 0.8, or 1.2 mg ecnoglutide or placebo as once-weekly injections for 20 weeks. All ecnoglutide doses achieved statistically significant HbA1c reductions versus placebo.
Key Findings
- HbA1c reductions: -1.81% (0.4 mg), -1.90% (0.8 mg), -2.39% (1.2 mg) vs -0.55% (placebo)
- 71.9% of 1.2 mg group achieved HbA1c of 6.5% or less versus 9.1% placebo
- 33.3% of 1.2 mg group achieved body weight reduction of 5% or more versus 3.0% placebo
- Safety profile consistent with GLP-1 receptor agonist class
Limitations: 20-week duration; Chinese population only; relatively small sample size (n=145); no active comparator arm
Efficacy and safety of ecnoglutide in adults with overweight or obesity: Phase 3 SLIMMER trial
Sciwind Biosciences investigators (2025) โข The Lancet Diabetes and Endocrinology
Phase 3 SLIMMER trial evaluating ecnoglutide in 664 Chinese adults with overweight or obesity over 48 weeks. Three dose groups (1.2 mg, 1.8 mg, 2.4 mg) versus placebo. The highest dose achieved 15.4% mean weight loss.
Key Findings
- 15.4% mean weight loss at 48 weeks with the highest dose
- 92.8% of participants achieved at least 5% weight loss at the highest dose
- 87% achieved 5% or more weight loss in the 2.4 mg group at week 40
- Safety profile consistent with GLP-1 receptor agonist class
Limitations: Chinese population only; 48-week duration; no cardiovascular outcomes endpoint; no active comparator
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
0View community protocolsExplore research gaps across all peptides โ | View clinical trial pipeline โ
๐Research Gaps & Future Directions
- โขNo data from non-Chinese populations; global clinical trials needed to assess generalizability
- โขNo cardiovascular outcomes data; no SELECT-equivalent trial planned
- โขLong-term safety and efficacy data beyond 48 weeks not available
- โขHead-to-head comparison with semaglutide or other approved GLP-1 agonists not conducted in humans
- โขThe clinical significance of cAMP-biased signaling versus balanced GLP-1 agonism requires further validation in long-term outcomes studies
- โขOral formulation (XW004) in early development with limited data
Research Overview#
Ecnoglutide (XW003) has been evaluated in a preclinical discovery program, Phase 1 dose-finding study, Phase 2 type 2 diabetes trial, and Phase 3 trials in both type 2 diabetes and obesity. The evidence base is moderate, supported by well-designed randomized controlled trials, though all clinical data to date are from Chinese populations only, limiting generalizability.
The biased agonism concept underlying ecnoglutide's design is scientifically novel and supported by in vitro pharmacology and preclinical efficacy data. However, the clinical significance of cAMP bias versus balanced GLP-1 agonism has not been conclusively demonstrated in comparative human studies.
Preclinical Discovery and Phase 1#
The discovery of ecnoglutide was published in Molecular Metabolism (Ren et al., 2023; PMID 37364710). The researchers systematically engineered GLP-1 analogs with the Ala8Val substitution and C18 fatty diacid at various positions to achieve cAMP signaling bias. Ecnoglutide emerged as the lead compound with an extreme signaling bias: cAMP EC50 of 0.018 nM versus receptor internalization EC50 of greater than 10,000 nM.
In preclinical models, ecnoglutide demonstrated superior weight loss and glycemic control compared to semaglutide at equivalent doses in rodent models. The Phase 1 trial established safety, tolerability, and a half-life of 124-138 hours at steady state supporting once-weekly dosing.
Phase 2 Type 2 Diabetes Trial#
The Phase 2 trial (Ji et al., 2024; PMID 39333121, Nature Communications) enrolled 145 adults with type 2 diabetes across multiple centers in China. This randomized, double-blind, placebo-controlled study evaluated three doses of ecnoglutide (0.4, 0.8, and 1.2 mg weekly) over 20 weeks.
All ecnoglutide doses achieved statistically significant HbA1c reductions versus placebo (P < 0.0001). The 1.2 mg dose produced a 2.39% HbA1c reduction, which is notable compared to typical GLP-1 agonist efficacy. The safety profile was consistent with the GLP-1 agonist class, with gastrointestinal events being the most common adverse effects.
Phase 3 SLIMMER Trial (Obesity)#
The SLIMMER trial was the pivotal Phase 3 obesity study, enrolling 664 Chinese adults with overweight or obesity. Results published in The Lancet Diabetes and Endocrinology showed that ecnoglutide 2.4 mg achieved 15.4% mean weight loss at 48 weeks, with 92.8% of participants achieving at least 5% weight loss. The safety profile was consistent with the GLP-1 agonist class, with adverse events reported in 93% of ecnoglutide-treated participants versus 84% in the placebo group.
Phase 3 EECOH-1 Trial (Type 2 Diabetes)#
The Phase 3 EECOH-1 trial enrolled 211 participants with type 2 diabetes at 33 sites in China, evaluating ecnoglutide 0.6 mg and 1.2 mg versus placebo for 24 weeks. Results demonstrated HbA1c reductions comparable to those achieved with dual GLP-1/GIP agonists.
Evidence Quality Assessment#
| Evidence Criterion | Assessment | Details |
|---|---|---|
| Study design | RCTs | Double-blind, placebo-controlled |
| Sample size | Moderate (n=145 Phase 2; n=664 Phase 3 obesity) | Adequate for primary endpoints |
| Population diversity | Limited | All Chinese populations |
| Active comparator | Not available | No head-to-head vs approved agents |
| CV outcomes | Not studied | No cardiovascular outcomes trial |
| Regulatory status | Not approved | Phase 3 in China |
| Long-term data | Up to 48 weeks | SLIMMER trial |
Key Research Gaps#
-
Population generalizability: All clinical data from Chinese populations only. Cross-ethnic efficacy and safety data are needed for global regulatory submissions.
-
Cardiovascular outcomes: No cardiovascular outcomes trial has been conducted or announced, unlike semaglutide (SELECT trial) which demonstrated 20% MACE reduction.
-
Active comparator data: No head-to-head comparison with approved GLP-1 agonists in human clinical trials, despite preclinical superiority over semaglutide.
-
Long-term safety: Data limited to 48 weeks maximum. Long-term effects of cAMP-biased GLP-1 agonism beyond one year are unknown.
-
Clinical significance of bias: While the molecular pharmacology is well characterized, whether cAMP bias translates to clinically meaningful advantages over balanced GLP-1 agonists remains to be demonstrated.
Related Reading#
Frequently Asked Questions About Ecnoglutide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.